Cargando…
Predictive Value of Max’s Giant Associated Protein Mutation in Outcomes of Lung Adenocarcinoma Patients Treated With Immune Checkpoint Inhibitors
Treatment with immune checkpoint inhibitors (ICIs) has considerably improved prognosis in multiple cancers. However, regardless of PD-L1 expression and TMB, better predictive biomarkers are required to identify ICI-responsive patients. We analyzed a pan-cancer cohort as the discovery cohort to ident...
Autores principales: | Qu, Yan, Wang, Chao, Liu, Lihui, Li, Sini, Zhang, Xue, Ma, Zixiao, Bai, Hua, Wang, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8558674/ https://www.ncbi.nlm.nih.gov/pubmed/34733843 http://dx.doi.org/10.3389/fcell.2021.728647 |
Ejemplares similares
-
BRAF Mutation as a Potential Therapeutic Target for Checkpoint Inhibitors: A Comprehensive Analysis of Immune Microenvironment in BRAF Mutated Colon Cancer
por: Cen, Shuyi, et al.
Publicado: (2021) -
Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genes
por: Hua, Linbin, et al.
Publicado: (2023) -
Prognostic Value of Genomic Instability of m(6)A-Related lncRNAs in Lung Adenocarcinoma
por: Li, Rui, et al.
Publicado: (2022) -
Glycolysis Define Two Prognostic Subgroups of Lung Adenocarcinoma With Different Mutation Characteristics and Immune Infiltration Signatures
por: Huo, Chen, et al.
Publicado: (2021) -
A Novel DNA Repair Gene Signature for Immune Checkpoint Inhibitor-Based Therapy in Gastric Cancer
por: Yuan, Binbin, et al.
Publicado: (2022)